The First and Only Sublingual Spray for Breakthrough Cancer Pain
SUBSYS (fentanyl sublingual spray) is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to opioid therapy for their underlying persistent pain. SUBSYS may be appropriate for patients experiencing breakthrough cancer pain episodes with early time-to-peak intensity.
Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60mg of oral morphine daily or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking SUBSYS.
What is SUBSYS?
It is the first and only fentanyl sublingual spray for the treatment of breakthrough cancer pain.
SUBSYS (fentanyl sublingual spray) is a proprietary, single-unit spray device that delivers 0.1mL (2-3 drops) of a fentanyl solution underneath the tongue to allow for absorption across the sublingual mucosa. SUBSYS is the only nonionized fentanyl in a form ready for absorption—no need for disintegration, dissolution or pH adjustment after dosing.
Breakthrough Cancer Pain Overview